Antimicrobial
Neuraminidase inhibitors
Block influenza virion release
noor-uh-MIN-ih-days in-HIB-ih-terz
High-yield clue
Neuraminidase inhibitors stop cleavage of sialic acid so new virions stay stuck to the host cell and cannot spread.
Overview
An antiviral class (oseltamivir, zanamivir, peramivir) whose mechanism concept is blocking the influenza surface enzyme neuraminidase, studied to connect viral enzyme structure to virion release.
Classification
- Antiviral
- Sialic-acid analog
- Influenza A and B activity
- Neuraminidase (N-spike) target
Lab & identification clues
- Neuraminidase enzyme cleaves host-cell sialic acid vocabulary
- Influenza has both hemagglutinin (H) and neuraminidase (N) spikes
- Resistance vocabulary tied to neuraminidase active-site mutations
Associations
- Influenza virus release mechanism concept
- Seasonal influenza study framing
- H and N surface glycoprotein antigen vocabulary
Commonly confused with
- M2 ion-channel blockers (amantadine)
- Baloxavir (endonuclease inhibitor)
Frequently asked questions
What is Neuraminidase inhibitors?
An antiviral class (oseltamivir, zanamivir, peramivir) whose mechanism concept is blocking the influenza surface enzyme neuraminidase, studied to connect viral enzyme structure to virion release.
What is the high-yield clue for Neuraminidase inhibitors?
Neuraminidase inhibitors stop cleavage of sialic acid so new virions stay stuck to the host cell and cannot spread.
What is Neuraminidase inhibitors associated with?
Neuraminidase inhibitors is associated with Influenza virus release mechanism concept, Seasonal influenza study framing, and H and N surface glycoprotein antigen vocabulary.
What is Neuraminidase inhibitors commonly confused with?
Neuraminidase inhibitors is commonly confused with M2 ion-channel blockers (amantadine) and Baloxavir (endonuclease inhibitor).
Original mechanism summary for microbiology study. Sources checked: CDC antimicrobial-resistance guidance, NCBI Bookshelf Medical Microbiology, and standard coursework frameworks; reviewed 2026-06. Covers class, mechanism, and resistance vocabulary only; no prescribing, dosing, or patient-specific treatment guidance.